tiprankstipranks
Optimizerx Corporation (OPRX)
NASDAQ:OPRX
US Market
Want to see OPRX full AI Analyst Report?

OptimizeRx (OPRX) Earnings Dates, Call Summary & Reports

600 Followers

Earnings Data

Report Date
Aug 06, 2026
TBA (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
0.1
Last Year’s EPS
0.24
Same Quarter Last Year
Based on 6 Analysts Ratings

Earnings Call Summary

Q1 2026
Earnings Call Date:May 12, 2026|
% Change Since:
|
Earnings Call Sentiment|Neutral
The call balanced encouraging operational and margin progress (strong adjusted EBITDA growth, improved gross margins, significant product traction with DAP and subscription growth, refinancing savings, and KPI improvements) against tangible near-term top-line challenges (10% YoY revenue decline, 15-20% contracted revenue shortfall, a major client disruption, reduced cash and negative operating cash flow, and a downward revision to revenue guidance). Management emphasized these headwinds are short-to-intermediate term and highlighted programmatic/DSP initiatives and subscription mix as drivers for 2027 recovery.
Company Guidance
OptimizeRx updated full‑year 2026 guidance to revenue of $95–100 million while maintaining adjusted EBITDA of $21–25 million, and expects full‑year gross margin in the high‑60% range with revenue weighted roughly 40/60 to the second half; Q1 results included revenue of $19.8M (down 10% y/y from $21.9M), adjusted EBITDA $3.3M (vs $1.5M), GAAP net loss $0.5M ($0.03/share), non‑GAAP net income $2.7M ($0.14/diluted share vs $1.5M/$0.08), operating cash flow of –$0.5M, cash of $20.2M (vs $23.4M), debt $23.6M (with $2.7M principal paid in Q1), and KPIs showing DAP product growth of 60% in Q1 with DAP subscription revenue up 45%, average revenue per top‑20 pharma $2.8M (top‑20 = 52% of business), net revenue retention of 110%, and revenue per FTE $801K (vs $710K); management also expects ~ $3M of annualized cash operating expense savings (≈ $1M in‑year 2026 benefit, ex‑severance), refinanced to a $25M term loan with a $10M revolver at SOFR+2.25% (vs prior SOFR+8.5%) for roughly $1.5M of annual interest savings, and highlighted programmatic DSP access (DSPs control >80% of digital promo dollars) to drive greater utilization of currently <10% network inventory into 2027.
Quarterly Revenue and Consensus Outperformance
Q1 revenue was $19.8M, and management stated the quarter exceeded consensus estimates on both top and bottom lines, despite YoY revenue decline.
Adjusted EBITDA Expansion
Adjusted EBITDA rose to $3.3M in Q1 2026 from $1.5M in Q1 2025, an increase of approximately 120%, reflecting improved operating leverage and margin optimization.
Non-GAAP Profitability Improvement
Non-GAAP net income increased to $2.7M ($0.14 diluted) from $1.5M ($0.08) year-over-year (≈80% increase). GAAP net loss narrowed to $0.5M from $2.2M in the prior year quarter.
Strong Product Momentum — DAP Growth
AI-enabled DAP solution grew 60% year-over-year in Q1, with DAP subscription revenue up 45%, indicating accelerating product-market fit and greater subscription mix for revenue visibility.
Gross Margin and Expense Improvements
Company now expects full-year gross margin in the high 60% range. Total expenses decreased by $4.6M YoY (driven by lower cost of revenue and G&A). Management expects cash operating expense reductions of ~$3M annualized, including ~$1M in-year benefit for 2026.
Key Operating KPIs and Revenue Productivity
Net revenue retention remained strong at 110%. Revenue per FTE improved to $801K from $710K in Q1 2025 (≈12.8% increase). Average revenue per top-20 pharmaceutical manufacturer stands at $2.8M; top-20 accounted for 52% of Q1 revenue.
Balance Sheet and Financing Improvement
Refinanced term loan to Fifth Third Bank with a fully drawn $25M term loan and access to a $10M revolver. Management cites approximately $1.5M in expected annual interest expense savings from the refinance.
Programmatic / DSP Opportunity
Company is enabling demand-side platforms that control >80% of digital promotional dollars into its EHR network, estimating current utilization of <10% of inventory and positioning programmatic as a potential long-term growth channel with meaningful upside.

OptimizeRx (OPRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

OPRX Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 06, 2026
2026 (Q2)
0.10 / -
0.24
May 12, 2026
2026 (Q1)
0.05 / 0.14
0.0875.00% (+0.06)
Mar 05, 2026
2025 (Q4)
0.22 / 0.51
0.370.00% (+0.21)
Nov 06, 2025
2025 (Q3)
0.04 / 0.20
0.1266.67% (+0.08)
Aug 07, 2025
2025 (Q2)
0.02 / 0.24
0.021100.00% (+0.22)
May 12, 2025
2025 (Q1)
-0.12 / 0.08
-0.11172.73% (+0.19)
Mar 12, 2025
2024 (Q4)
0.27 / 0.30
0.2615.38% (+0.04)
Nov 13, 2024
2024 (Q3)
0.06 / 0.12
0.0933.33% (+0.03)
Aug 08, 2024
2024 (Q2)
-0.06 / 0.02
-0.01300.00% (+0.03)
May 14, 2024
2024 (Q1)
- / -
-0.09
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

OPRX Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 12, 2026
$6.34$4.92-22.48%
Mar 05, 2026
$7.53$6.74-10.49%
Nov 06, 2025
$18.94$15.65-17.37%
Aug 07, 2025
$12.84$17.30+34.74%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Optimizerx Corporation (OPRX) report earnings?
Optimizerx Corporation (OPRX) is schdueled to report earning on Aug 06, 2026, TBA (Confirmed).
    What is Optimizerx Corporation (OPRX) earnings time?
    Optimizerx Corporation (OPRX) earnings time is at Aug 06, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is OPRX EPS forecast?
          OPRX EPS forecast for the fiscal quarter 2026 (Q2) is 0.1.